Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against Multiple Indications
Shots:
- AbCellera to receive upfront- milestone- and royalties based on the development and commercialization of Abs- emerge under the collaboration
- The expanded collaboration will utilize AbCellera’s technology stack- which includes Trianni Mouse and OrthoMab protein engineering platform
- AbCellera will generate panels of Abs against up to 8 new targets across multiple indications- selected by Gilead
Ref: BusinessWire | Image: Gilead
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com